Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words '(-)-DEPRENYL' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 551 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Katagi, M; Tatsuno, M; Miki, A; Nishikawa, M; Nakajima, K; Tsuchihashi, H
      Simultaneous determination of selegiline-N-oxide, a new indicator for selegiline administration, and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry

      JOURNAL OF CHROMATOGRAPHY B
    2. Naoi, M; Maruyama, W
      Future of neuroprotection in Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    3. Salinas, M; Martin, D; Alvarez, A; Cuadrado, A
      Akt1/PKB alpha protects PC12 cells against the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium and reduces the levels of oxygen-free radicals

      MOLECULAR AND CELLULAR NEUROSCIENCE
    4. Fowler, JS; Ding, YS; Logan, J; MacGregor, RR; Shea, C; Garza, V; Gimi, R; Volkow, ND; Wang, GJ; Schlyer, D; Ferrieri, R; Gatley, SJ; Alexoff, D; Carter, P; King, P; Pappas, N; Arnett, CD
      Species differences in [C-11]clorgyline binding in brain

      NUCLEAR MEDICINE AND BIOLOGY
    5. Yoneda, F; Moto, T; Sakae, M; Ohde, H; Knoll, B; Miklya, I; Knoll, J
      Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain

      BIOORGANIC & MEDICINAL CHEMISTRY
    6. Oka, T; Yasusa, T; Ando, T; Watanabe, M; Yoneda, F; Ishida, T; Knoll, J
      Enantioselective synthesis and absolute configuration of (-)-1-(benzofuran-2-yl)-2-propylaminopentane ((-)-BPAP), a highly potent and selective catecholaminergic activity enhancer

      BIOORGANIC & MEDICINAL CHEMISTRY
    7. Nakai, S; Yoneda, F
      Theoretical investigation of (-)1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP] as a hydroxyl radical scavenger

      BIOORGANIC & MEDICINAL CHEMISTRY
    8. Barbelivien, A; Nyman, L; Haapalinna, A; Sirvio, J
      Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks

      PHARMACOLOGY & TOXICOLOGY
    9. Pelat, M; Verwaerde, P; Tran, MA; Berlan, M; Senard, JM; Montastruc, JL
      Changes in vascular alpha1-and alpha2-adrenoceptor responsiveness by selegiline treatment

      FUNDAMENTAL & CLINICAL PHARMACOLOGY
    10. Anisimov, VN
      Life span extension and cancer risk: myths and reality

      EXPERIMENTAL GERONTOLOGY
    11. Jankovic, J
      Parkinson's diseasetherapy: treatment of early and late disease

      CHINESE MEDICAL JOURNAL
    12. Grasing, K; Azevedo, R; Karuppan, S; Ghosh, S
      Biphasic effects of selegiline on striatal dopamine: Lack of effect on methamphetamine-induced dopamine depletion

      NEUROCHEMICAL RESEARCH
    13. MohanKumar, PS; MohanKumar, SMJ; Quadri, SK
      Deprenyl stimulates the efflux of monoamines from the rat hypothalamus in vitro

      BRAIN RESEARCH BULLETIN
    14. Ito, D; Amano, T; Sato, H; Fukuuchi, Y
      Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease

      JOURNAL OF NEUROLOGY
    15. Pryse-Phillips, W; Sternberg, S; Rochon, P; Naglie, G; Strong, H; Feightner, J
      The use of medications for cognitive enhancement

      CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
    16. Matsubara, K; Senda, T; Uezono, T; Awaya, T; Ogawa, S; Chiba, K; Shimizu, K; Hayase, N; Kimura, K
      L-deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP+ and beta-carbolinium: a microdialysis study in rats

      NEUROSCIENCE LETTERS
    17. Kupsch, A; Sautter, J; Gotz, ME; Breithaupt, W; Schwarz, J; Youdim, MBH; Riederer, P; Gerlach, M; Oertel, WH
      Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

      JOURNAL OF NEURAL TRANSMISSION
    18. Haberle, D; Szoko, E; Halasz, AS; Magyar, K
      The effect of low oral doses of (-)-deprenyl and its metabolites on DSP-4 toxicity

      JOURNAL OF NEURAL TRANSMISSION
    19. Maruyama, W; Boulton, AA; Davis, BA; Dostert, P; Naoi, M
      Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine

      JOURNAL OF NEURAL TRANSMISSION
    20. Szende, B; Bokonyi, G; Bocsi, J; Keri, G; Timar, F; Magyar, K
      Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites

      JOURNAL OF NEURAL TRANSMISSION
    21. Mills, D; Ledger, R
      The effects of oral selegiline hydrochloride on learning and training in the dog: A psychobiological interpretation

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    22. Sloley, BD; Urichuk, LJ; Lei, L; Coutts, RT; Baker, GB; Shan, JJ; Pang, PKT
      Monoamine oxidase inhibition and neuroprotection by N-1-propargylphenelzine

      DRUG DEVELOPMENT RESEARCH
    23. Wayment, HK; Schenk, JO; Sorg, BA
      Characterization of extracellular dopamine clearance in the medial prefrontal cortex: Role of monoamine uptake and monoamine oxidase inhibition

      JOURNAL OF NEUROSCIENCE
    24. Peterson, ME
      Medical treatment of canine pituitary dependent hyperadrenocorticism (Cushing's disease)

      VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE
    25. Hidestrand, M; Oscarson, M; Salonen, JS; Nyman, L; Pelkonen, O; Turpeinen, M; Ingelman-Sundberg, M
      CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes

      DRUG METABOLISM AND DISPOSITION
    26. Fenwick, AE
      Chapter 29. New developments in animal healthcare

      ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 36
    27. Bodkin, JA; Kwon, AE
      Selegiline and other atypical monoamine oxidase inhibitors in depression

      PSYCHIATRIC ANNALS
    28. Liou, HH; Chen, RC; Chen, THH; Tsai, YF; Tsai, MC
      Attenuation of paraquat-induced dopaminergic toxicity on the substantia nigra by (-)-deprenyl in vivo

      TOXICOLOGY AND APPLIED PHARMACOLOGY
    29. Fowler, JS; Volkow, ND; Logan, J; Franceschi, D; Wang, GJ; MacGregor, R; Shea, C; Garza, V; Pappas, N; Carter, P; Netusil, N; Bridge, P; Liederman, D; Elkashef, A; Rotrosen, J; Hitzemann, R
      Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain

      LIFE SCIENCES
    30. Hauptmann, N; Shih, JC
      2-Naphthylamine, a compound found in cigarette smoke, decreases both monoamine oxidase A and B catalytic activity

      LIFE SCIENCES
    31. Fowler, JS; Logan, J; Ding, YS; Franceschi, D; Wang, GJ; Volkow, ND; Pappas, N; Schlyer, D; Gatley, SJ; Alexoff, D; Felder, C; Biegon, A; Zhu, W
      Non-MAO A binding of clorgyline in white matter in human brain

      JOURNAL OF NEUROCHEMISTRY
    32. Steyn, SJ; Castagnoli, K; Steyn, S; Castagnoli, N
      Selective inhibition of MAO-B through chronic low-dose (R)-deprenyl treatment in C57BL/6 mice has no effect on basal neostriatal dopamine levels

      EXPERIMENTAL NEUROLOGY
    33. Puurunen, K; Jolkkonen, J; Sirvio, J; Haapalinna, A; Sivenius, J
      Selegiline combined with enriched-environment housing attenuates spatial learning deficits following focal cerebral ischemia in rats

      EXPERIMENTAL NEUROLOGY
    34. Simon, L; Szilagyi, G; Bori, Z; Orbay, P; Nagy, Z
      (-)-D-deprenyl attenuates apoptosis in experimental brain ischaemia

      EUROPEAN JOURNAL OF PHARMACOLOGY
    35. Shimazu, S; Takahata, K; Katsuki, H; Tsunekawa, H; Tanigawa, A; Yoneda, F; Knoll, J; Akaike, A
      (-)-1-(benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release

      EUROPEAN JOURNAL OF PHARMACOLOGY
    36. Koutsilieri, E; Scheller, C; Sopper, S; Gotz, ME; Gerlach, M; ter Meulen, V; Riederer, P
      Selegiline completely restores choline acetyltransferase activity deficitsin simian immunodeficiency infection

      EUROPEAN JOURNAL OF PHARMACOLOGY
    37. Youdim, MBH; Gross, A; Finberg, JPM
      Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

      BRITISH JOURNAL OF PHARMACOLOGY
    38. Unal, I; Gursoy-Ozdemir, Y; Bolay, H; Soylemezoglu, F; Saribas, O; Dalkara, T
      Chronic daily administration of selegiline and EGb 761 increases brain's resistance to ischemia in mice

      BRAIN RESEARCH
    39. Muralikrishnan, D; Ebadi, M
      SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity

      BRAIN RESEARCH
    40. Kumlien, E; Nilsson, A; Hagberg, G; Langstrom, B; Bergstrom, M
      PET with C-11-deuterium-deprenyl and F-18-FDG in focal epilepsy

      ACTA NEUROLOGICA SCANDINAVICA
    41. Nakai, S; Yoneda, F
      A theoretical investigation of (-)-deprenyl (selegiline) as a radical scavenger

      THEORETICAL CHEMISTRY ACCOUNTS
    42. Rinne, UK
      Treatment of early Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    43. Lyytinen, J; Kaakkola, S; Gordin, A; Kultalahti, ER; Teravainen, H
      Entacapone and selegiline with L-dopa in patients with Parkinson's disease: an interaction study

      PARKINSONISM & RELATED DISORDERS
    44. Foley, P; Gerlach, M; Youdim, MBH; Riederer, P
      MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?

      PARKINSONISM & RELATED DISORDERS
    45. Bariska, J; Csermely, T; Furst, S; Kalasz, H; Bathori, M
      Displacement thin-layer chromatography

      JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
    46. Scheife, RT; Schumock, GT; Burstein, A; Gottwald, MD; Luer, MS
      Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    47. Rose, LM; Ohlinger, WJ; Mauro, VF
      A hypertensive reaction induced by concurrent use of selegiline and dopamine

      ANNALS OF PHARMACOTHERAPY
    48. Finotti, N; Castagna, L; Moretti, A; Marzatico, F
      Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment

      PHARMACOLOGICAL RESEARCH
    49. Logan, J; Fowler, JS; Volkow, ND; Wang, GJ; MacGregor, RR; Shea, C
      Reproducibility of repeated measures of deuterium substituted [C-11]L-deprenyl ([C-11]L-deprenyl-D2) binding in the human brain

      NUCLEAR MEDICINE AND BIOLOGY
    50. Erdo, F; Baranyi, A; Takacs, J; Aranyi, P
      Different neurorescue profiles of selegiline and p-fluoro-selegiline in gerbils

      NEUROREPORT
    51. Fredriksson, A; Palomo, T; Archer, T
      Effects of MAO inhibitors upon MPTP mice chronically treated with suprathreshold doses of L-dopa

      BEHAVIOURAL PHARMACOLOGY
    52. Andringa, G; van Oosten, RV; Unger, W; Hafmans, TGM; Veening, J; Stoof, JC; Cools, AR
      Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra

      EUROPEAN JOURNAL OF NEUROSCIENCE
    53. Stone, TW; Behan, WMH; MacDonald, M; Darlington, LG
      Possible mediation of quinolinic acid-induced hippocampal damage by reactive oxygen species

      AMINO ACIDS
    54. Fariello, RG; Maj, R; Marrari, P; Beard, D; Algate, C; Salvati, P
      Acute behavioral and EEG effects of NW-1015 on electrically-induced afterdischarge in conscious monkeys

      EPILEPSY RESEARCH
    55. Montgomery, EB; Koller, WC; LaMantia, TJK; Newman, MC; Swanson-Hyland, E; Kaszniak, AW; Lyons, K
      Early detection of probable idiopathic Parkinson's disease: I. Developmentof a diagnostic test battery

      MOVEMENT DISORDERS
    56. Khaldy, H; Escames, G; Leon, J; Vives, F; Luna, JD; Acuna-Castroviejo, D
      Comparative effects of melatonin, L-deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro

      JOURNAL OF PINEAL RESEARCH
    57. Shite, J; Dong, E; Kawai, H; Stevens, SY; Liang, CS
      Selegiline improves cardiac sympathetic terminal function and beta-adrenergic responsiveness in heart failure

      AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
    58. Montastruc, JL; Chaumerliac, C; Desboeuf, K; Manika, M; Bagheri, H; Rascol, O; Lapeyre-Mestre, M
      Adverse drug reactions to selegiline: A review of the French Pharmacovigilance Database

      CLINICAL NEUROPHARMACOLOGY
    59. Laine, K; Anttila, M; Huupponen, R; Maki-Ikola, O; Heinonen, E
      Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding

      CLINICAL NEUROPHARMACOLOGY
    60. Musshoff, F
      Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine

      DRUG METABOLISM REVIEWS
    61. Thal, LJ
      Trials to slow progression and prevent disease onset

      JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT
    62. Naoi, M; Maruyama, W; Takahashi, T; Akao, Y; Nakagawa, Y
      Involvement of endogenous N-methyl(R) salsolinol in Parkinson's disease: induction of apoptosis and protection by (-)deprenyl

      JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT
    63. Frey, U; Retz, W; Riederer, P; Rosler, M
      New aspects in antidemential drug therapy of Alzheimer's disease

      AKTUELLE NEUROLOGIE
    64. Kuhmonen, J; Jolkkonen, J; Haapalinna, A; Sivenius, J
      The neuroprotective effects of (-)deprenyl in the gerbil hippocampus following transient global ischemia

      JOURNAL OF NEURAL TRANSMISSION
    65. Prat, G; Perez, V; Rubio, A; Casas, M; Unzeta, M
      The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats

      JOURNAL OF NEURAL TRANSMISSION
    66. Kwan, E; Baker, GB; Shuaib, A; Ling, L; Todd, KG
      N-methyl,N-propargyl-2-phenylethylamine (MPPE), an analog of deprenyl, increases neuronal cell survival in thiamin deficiency encephalopathy

      DRUG DEVELOPMENT RESEARCH
    67. Weinstock, M; Goren, T; Youdim, MBH
      Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities

      DRUG DEVELOPMENT RESEARCH
    68. Abu-Raya, S; Blaugrund, E; Trembovler, V; Lazarovici, P
      Rasagiline, a novel monoamine oxidase-B inhibitor with neuroprotective effects under ischemic conditions in PC12 cells

      DRUG DEVELOPMENT RESEARCH
    69. Hamabe, W; Fujita, R; Yasusa, T; Yoneda, F; Yoshida, A; Ueda, H
      (-)1-(Benzofuran-2-yl)-2-propylaminopentane shows survival effect on cortical neurons under serum-free condition through sigma receptors

      CELLULAR AND MOLECULAR NEUROBIOLOGY
    70. Thomas, T
      Monoamine oxidase-B inhibitors in the treatment of Alzheimers disease

      NEUROBIOLOGY OF AGING
    71. Groc, L; Levine, RA; Foster, JA; Normile, HJ; Weissmann, D; Bezin, L
      Evidence of deprenyl-insensitive apoptosis of nigral dopamine neurons during development

      DEVELOPMENTAL BRAIN RESEARCH
    72. De Angelis, L; Furlan, C
      The anxiolytic-like properties of two selective MAOIs, moclobemide and selegiline, in a standard and an enhanced light/dark aversion test

      PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
    73. Durden, DA; Dyck, LE; Davis, BA; Liu, YD; Boulton, AA
      Metabolism and pharmacokinetics, in the rat, of (R)-N-(2-heptyl)methylpropargylamine (R-2HMP), a new potent monoamine oxidase inhibitor and antiapoptotic agent

      DRUG METABOLISM AND DISPOSITION
    74. Maruyama, W; Yamamoto, T; Kitani, K; Carrillo, MC; Youdim, M; Naoi, M
      Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline

      MECHANISMS OF AGEING AND DEVELOPMENT
    75. Pardon, MC; Joubert, C; Perez-Diaz, F; Christen, Y; Launay, JM; Cohen-Salmon, C
      In vivo regulation of cerebral monoamine oxidase activity in senescent controls and chronically stressed mice by long-term treatment with Ginkgo biloba extract (EGb 761)

      MECHANISMS OF AGEING AND DEVELOPMENT
    76. Alafuzoff, I; Helisalmi, S; Heinonen, EH; Reinikainen, K; Hallikainen, M; Soininen, H; Koivisto, K
      Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    77. Langston, JW; Tanner, CM
      Selegiline and Parkinson's disease - It's deja vu - again

      NEUROLOGY
    78. Waldmeier, PC; Spooren, WPJM; Hengerer, B
      CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease

      NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
    79. Carlile, GW; Chalmers-Redman, RME; Tatton, NA; Pong, A; Borden, KE; Tatton, WG
      Reduced apoptosis after nerve growth factor and serum withdrawal: Conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer

      MOLECULAR PHARMACOLOGY
    80. Knoll, J; Miklya, I; Knoll, B; Dallo, J
      Sexual hormones terminate in the rat - The significantly enhanced catecholaminergic/serotoninergic tone in the brain characteristic to the post-weaning period

      LIFE SCIENCES
    81. Carrillo, MC; Minami, C; Kitani, K; Maruyama, W; Ohashi, K; Yamamoto, Y; Naoi, M; Kanai, S; Youdim, MBH
      Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat

      LIFE SCIENCES
    82. Wu, WR; Zhu, ZT; Zhu, XZ
      Differential effects of L-deprenyl on MPP+- and MPTP-induced dopamine overflow in microdialysates of striatum and nucleus accumbens

      LIFE SCIENCES
    83. Carrillo, MC; Kanai, S; Kitani, K; Ivy, GO
      A high dose of long term treatment with deprenyl loses its effect on antioxidant enzyme activities as well as on survivals of Fischer-344 rats

      LIFE SCIENCES
    84. Fowler, JS; Wang, GJ; Volkow, ND; Logan, J; Franceschi, D; Franceschi, M; MacGregor, R; Shea, C; Garza, V; Liu, N; Ding, YS
      Evidence that Ginkgo biloba extract does not inhibit MAO A and B in livinghuman brain

      LIFE SCIENCES
    85. Klegeris, A; McGeer, PL
      R-(-)-deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition

      EXPERIMENTAL NEUROLOGY
    86. Zhu, J; Hamm, RJ; Reeves, TM; Povlishock, JT; Phillips, LL
      Postinjury administration of L-deprenyl improves cognitive function and enhances neuroplasticity after traumatic brain injury

      EXPERIMENTAL NEUROLOGY
    87. Valoti, M; Fusi, F; Frosini, M; Pessina, F; Tipton, KF; Sgaragli, GP
      Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, beta-naphthoflavone and L-deprenyl

      EUROPEAN JOURNAL OF PHARMACOLOGY
    88. Suuronen, T; Kolehmainen, P; Salminen, A
      Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells

      BIOCHEMICAL PHARMACOLOGY
    89. Mizuta, I; Ohta, M; Ohta, K; Nishimura, M; Mizuta, E; Hayashi, K; Kuno, S
      Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesisin cultured mouse astrocytes

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    90. Munzar, P; Goldberg, SR
      Dopaminergic involvement in the discriminative-stimulus effects of methamphetamine in rats

      PSYCHOPHARMACOLOGY
    91. Ohta, S
      Isoquinolines in Parkinson's disease

      NEUROTOXIC FACTORS IN PARKINSON'S DISEASE AND RELATED DISORDERS
    92. Woodroofe, CC; Mostashari, R; Lu, XL; Ramsay, RR; Silverman, RB
      Selective inhibition of monoamine oxidase B by aminoethyl substituted benzyl ethers

      JOURNAL OF ENZYME INHIBITION
    93. Landsberg, G
      Identification and medical management of cognitive dysfunction syndrome and other geriatric behavior problems

      VETERINARY MEDICINE
    94. Nakai, S; Yoneda, F; Yamabe, T; Fukui, K
      Inhibition mechanism of flavin by deprenyl as an acetylenic irreversible inhibitor

      THEORETICAL CHEMISTRY ACCOUNTS
    95. Makino, Y; Suzuki, A; Ogawa, T; Shirota, O
      Direct determination of methamphetamine enantiomers in urine by liquid chromatography with a strong cation-exchange precolumn and phenyl-beta-cyclodextrin-bonded semi-microcolumn

      JOURNAL OF CHROMATOGRAPHY B
    96. Yu, PH; Davis, BA
      Inversion of selectivity of N-substituted propargylamine monoamine oxidaseinhibitors following structural modifications to quaternary salts

      INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
    97. Czub, M; Czub, S; Gosztonyi, G; Koutsilieri, E; Sopper, S; Muller, JG; Gerlach, M; Riederer, P; ter Meulen, V
      Effects of Selegiline in a retroviral rat model for neurodegenerative disease

      JOURNAL OF NEUROVIROLOGY
    98. ThyagaRajan, S; Quadri, SK
      L-deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors

      ENDOCRINE
    99. Larsen, JP; Boas, J; Erdal, JE
      Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study

      EUROPEAN JOURNAL OF NEUROLOGY
    100. Przuntek, T; Conrad, B; Dichgans, J; Kraus, PH; Krauseneck, P; Pergande, G; Rinne, U; Schimrigk, K; Schnitker, J; Vogel, HP
      SELEDO: a 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa

      EUROPEAN JOURNAL OF NEUROLOGY


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 15:24:57